• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Pfizer Inc.

    5/30/25 1:07:24 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email
    SD 1 formsdye2024.htm SD Document

    . 
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM SD
     
    Specialized Disclosure Report
     
    PFIZER INC.
    (Exact name of registrant as specified in its charter)
     
    DELAWARE
    (State or Other Jurisdiction of Incorporation)
     
    1-3619 13-5315170
    (Commission
    File Number)
     
    (I.R.S. Employer Identification No.)
    66 Hudson Boulevard East
    New York, New York
    10001-2192
    (Address of Principal Executive Offices) (Zip Code)
    Margaret M. Madden, Esq.
    Vice President and Corporate Secretary,
    Chief Counsel – Corporate Governance
    (212) 733-2323

    (Name and telephone number, including area code, of the person to contact in connection with this report)
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed submitted, and provide the period to which the information in this Form applies:
     
    x    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _____ .

     




    Section 1 — Conflict Minerals Disclosure
     
    Item 1.01 Conflict Minerals Disclosure and Report

    As provided in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD, a Conflict Minerals Report is provided as an Exhibit to this Form SD and is also available on the Internet at: http://www.pfizer.com/investors/sec_filings. Information on our website shall not be deemed incorporated into, or be a part of, this Form SD or the Conflict Minerals Report.

    Information concerning tantalum, tungsten, tin and gold from recycled or scrap sources that may be contained in our in-scope product is included in the Conflict Minerals Report and is incorporated in this Form SD by reference.
     
    Item 1.02 Exhibit
     
    The Conflict Minerals Report required by Item 1.01 is filed as Exhibit 1.01 to this Form SD.
     

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 — Exhibits
     
    Item 3.01 Exhibits
     
    Exhibit 1.01 — Conflict Minerals Report for the calendar year ended December 31, 2024.





     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    PFIZER INC.
    (Registrant)
     
     

    By: /s/ Douglas M. Lankler
    Date:  May 30, 2025
    Name: Douglas M. Lankler
    Title: Chief Legal Officer, Executive Vice
                President



    Get the next $PFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PFE

    DatePrice TargetRatingAnalyst
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    12/10/2024$29.00Neutral
    BofA Securities
    11/15/2024$25.00Underperform
    Wolfe Research
    10/25/2024$30.00Neutral
    Citigroup
    10/17/2024$32.00Mkt Perform
    Bernstein
    8/7/2024Neutral → Outperform
    Daiwa Securities
    3/22/2024Buy → Hold
    Argus
    2/23/2024$36.00Buy
    Guggenheim
    More analyst ratings